Table 4.
Indication | Medication | Dosing Regimen | Comments |
---|---|---|---|
Tinea capitis: Diffuse/inflammatory tinea corporis treatment | |||
Adult | Terbinafine | 250 mg, PO, daily for 2-4 wk | Potential rare hepatotoxicity, anemia, neutropenia, thrombocytopenia, agranulocytosis. LFT elevations in approximately 3%-4% treated. Possible gastrointestinal upset. Obtain baseline CBC and LFT and repeat every 4-6 wk during treatment. |
Itraconazole | 200 mg, PO, daily for 2-6 wk | Potential rare hepatotoxicity. LFT elevations in approximately 2%-4% treated. Possible gastrointestinal upset. Obtain baseline LFT and repeat every 4-6 wk during treatment. | |
Ketoconazole | 200 mg, PO, daily for 2-4 wk | Potential severe hepatotoxicity/hepatic failure (1:10,000 treated), hemolytic anemia, neutropenia. Possible gastrointestinal upset. Avoid alcohol because of liver effects and disulfiram-type effect. Obtain baseline CBC and LFT and repeat every month during treatment. | |
Children | Griseofulvin (micronized) | 20 mg/kg, PO, daily for 8 wk | For child >30 kg. Rare hepatotoxicity and photosensitivity. Possible leukopenia and granulocytopenia. Possible gastrointestinal upset. Obtain CBC and LFT at 6 wk of treatment. |
Terbinafine | Weight, 10-20 kg: 62.5 mg, PO, daily for 2-4 wk | For child >2 years old. Potential rare hepatotoxicity, anemia, neutropenia, thrombocytopenia, agranulocytosis. LFT elevations in approximately 3%-4% treated. Possible gastrointestinal upset. Obtain baseline CBC and LFT and repeat every 4-6 wk during treatment. | |
Weight, 20-40 kg: 125 mg, PO, daily for 2-4 wk | |||
Weight >40 kg: same as adult dosing | |||
Tinea corporis: Limited area treatment | |||
Clotrimazole cream | Applied to lesion and surrounding area twice daily | ||
Miconazole cream | Applied to lesion and surrounding area twice daily | ||
Terbinafine cream | Applied to lesion and surrounding area twice daily | ||
Butenafine cream | Applied to lesion and surrounding area once daily | ||
Prophylaxis | |||
Adult | Fluconazole | 100 mg, PO, 1x/wk | Rare severe hepatotoxicity/hepatic failure, leukopenia, thrombocytopenia, agranulocytosis. Possible gastrointestinal upset. Avoid alcohol because of liver effects and disulfiram-type effect. Obtain baseline CBC and LFT and repeat every 4-6 wk during treatment. |
CBC, complete blood count; LFT, liver function test; PO, orally.